05) (Figures 6A-B). Additionally, no AMN-107 clinical trial significant treatment × time interaction (F = 0.29, η 2 = 0.03, p = .84) or treatment
effect were observed in testosterone/cortisol ratio at pre-test (CAF + PLA vs. CAF + CHO vs. PLA + CHO vs. PLA + PLA; 2.04 ± 0.83 vs. 1.93 ± 0.62 vs. 2.12 ± 0.59 vs. 2.24 ± 1.20, p > .05) or at post-test (CAF + PLA vs. CAF + CHO vs. PLA + CHO vs. PLA + PLA; 2.03 ± 0.36 vs. 1.90 ± 0.82 vs. 2.00 ± 0.85 vs. 1.91 vs. 0.76, p > .05). Figure 6 Changes in serum testosterone (A) and cortisol (B) concentrations in the conditions of caffeine + placebo (CAF + PLA), caffeine + carbohydrate (CAF + CHO), placebo + carbohydrate (PLA + CHO), and placebo + placebo (PLA + PLA). * = significant increase from pre-test (p < .01). AZD1152 in vitro Values are mean ± standard deviation. AT-test performance The results show that a significant agility performance interaction did not exist (F = 2.14, η 2 = 0.18, p > .05), as well no significant main effects
for time or treatment (Figure 7). Speed decrement was not significantly different among conditions (CAF + PLA vs. CAF + CHO vs. PLA + CHO vs. PLA + PLA, −3.06 ± 5.90% vs. -2.98 ± 3.96% vs. -0.14 ± 2.98% vs. -1.39 ± 4.46%; F = 2.14, η 2 = 0.18, p > .05). However, agility performance in the PLA + CHO condition was relatively well-preserved compared to the other treatments. Figure 7 Changes in agility T-test ( AT-test ) performance for the conditions of caffeine + placebo ICG-001 cost (CAF + PLA), caffeine + carbohydrate
(CAF + CHO), placebo + carbohydrate (PLA + CHO), and placebo + placebo (PLA + PLA). RSE: repeated sprint exercise. Values are mean ± standard deviation. Side effects All participants filled out the side effect questionnaire to assess Teicoplanin the possible adverse reaction 60-min after ingesting caffeine or placebo capsule. After ingestion of caffeine, one participant experienced anxiety and slight tremor, another experienced diarrhea, and a third experienced headache and flatulence. However, carbohydrate alone or placebo supplementation did not result in any uncomfortable issues for participants. Discussion To our knowledge, the present study is the first to examine the effects of caffeine (6 mg · kg−1) combined with carbohydrate (0.8 g · kg−1) administration on repeated sprint performance (10 sets of 5 × 4-s sprint with 20-s rest between each sprint) and agility in female athletes. The main findings indicate a significant increase in peak power, mean power, and total work with carbohydrate ingestion alone prior to commencing a repeated sprint exercise protocol. However, the sprint decrement and agility performance for the CAF + PLA, CAF + CHO, PLA + CHO, and PLA + PLA conditions were not statistically different.